AusCann Group Announced Research & Development Facility Acquisition

AusCann Group Announced Research & Development Facility Acquisition

AusCann Group Holdings Limited (ASX: AC8) had made an announcement of the acquisition of Research and Development Facility with the help of press release. As per the press release dated January 25, 2019, the company stated that they have wrapped up the Research & Development facility acquisition in Perth, Western Australia. The issued release state that the facility would be aiming towards the company’s cannabinoid pharmaceutical product pipeline which would provide the help related to the development of innovative formulations as well as dose forms. The company had also stated that site establishment happens to be a strategic move for the company and represents a crucial component of the development plans of AusCann Group Holdings Limited. 

The release issued by the company had stated that the research and development activities provide the support to the products of AusCann Group in terms of the quality. The company stated that it is focused on the patient-centered innovation and it would be working towards goals related to improving the health outcomes as well as which would build the company value. We would now see what AusCann Group Holdings Limited’s management has to say about the acquisition which has been mentioned above. The top management of AusCann Group Holdings Limited reflected positive views for the acquisition. It stated that the acquisition happens to be a major step for the company and, as a result, it would support the company in building the state of the art, fully integrated facility for the medicinal cannabis. The management of the company stated that 2019 would be an important year for the company as it has plans to roll out hard-shell cannabinoid capsules which would be catering to the stability and consistency of dose needed. The release also contained information related to the purchase price which was involved in the acquisition.

The company stated that the research and development facility involved purchase price amounting to $5.25 million and there are expectations that the company would be deploying additional funds of up to $6 million moving forward. We would now be looking at today’s performance of the company’s stock as well as how the stock of AusCann Group Holdings Limited has performed in the past few months.

On January 25, 2019, the company’s stock price closed in green as the stock price closed at A$0.655 per share which implies the rise of A$0.020 per share or 3.15%. The market capitalization of AusCann Group Holdings Limited stood at $196.27 million. The stock price of the company is trading towards the lower levels. Talking about the past performance, the company’s stock has given -38.35% return in the span of six months. In the time frame of previous three months, the stock had delivered the return of -15.33%. However, the company’s stock has posted the returns of 23.30% in the span of previous one month. As per Australian Securities Exchange of ASX, the earnings per share (or EPS) of AusCann Group Holdings Limited stood at A$-0.028.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Facebook Comments

Join Our Discussion

Sponsored ad by Kalkine

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here